Skip to main content
S&P 5007,684.48+0.01%DOW51,386.86-0.18%NASDAQ26,836.83+0.06%GOLD$4,199.80+0.75%OIL$91.30-1.40%
Delayed
Smart Investors Daily
AD

NASDAQ · ADAG

Adagene Inc.

Healthcare · Biotechnology

$3.20

Up+$0.02 (+0.62%)

Updated Sep 29, 2026, 2:21 PM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
111.61M
P/E ratio
-2.9
Dividend yield
0.00%
52-week range
$1.30 – $4.85
Volume
529.85K
Avg. volume
119.56K

Price performance · ADAG

ADAG price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 28, 2026

ADAG closed at $3.20 after 20 trading sessions, down 8.83% for the selected period.

Last close
$3.20
Period change
-8.83%
Period low
$2.93
Period high
$3.69
Daily close
View OHLC price history
ADAG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 28, 2026$2.94$3.21$2.87$3.20529.85K
Sep 25, 2026$2.96$3.185$2.87$2.93197.66K
Sep 24, 2026$2.94$3.01$2.81$2.98317.09K
Sep 23, 2026$3.16$3.22$2.92$2.97208.02K
Sep 22, 2026$3.31$3.3379$3.215$3.23226.33K
Sep 21, 2026$3.34$3.35$3.18$3.2197.78K
Sep 18, 2026$3.37$3.505$3.1713$3.31287.04K
Sep 17, 2026$3.30$3.4192$3.17$3.37261.08K
Sep 16, 2026$3.00$3.2368$2.92$3.17319.28K
Sep 15, 2026$3.385$3.385$2.925$2.97626.15K
Sep 14, 2026$3.38$3.60$3.235$3.27155.08K
Sep 11, 2026$3.36$3.48$3.2385$3.40258.87K
Sep 10, 2026$3.54$3.5519$3.20$3.31224.59K
Sep 9, 2026$3.61$3.69$3.24$3.27267.53K
Sep 8, 2026$3.55$3.61$3.45$3.49193K
Sep 4, 2026$3.67$3.6921$3.56$3.5828.19K
Sep 3, 2026$3.71$3.85$3.56$3.69167.71K
Sep 2, 2026$3.60$3.74$3.5999$3.69102.67K
Sep 1, 2026$3.51$3.675$3.42$3.64120.55K
Aug 31, 2026$3.62$3.62$3.4512$3.51131.62K

Latest ADAG news

The latest Smart Investors Daily articles mentioning ADAG.

Stock researchCompany · Overview

ADAG research

Overview

Company profile and research snapshot.

Company profile

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.00
Implied upside
—
Analysts
14
ADAG recent ratings
DateFirmRatingTarget
Sep 14, 2026HC Wainwright & Co.Buy—
Sep 10, 2026Chardan CapitalBuy—
Apr 6, 2026GuggenheimBuy—
Nov 24, 2025GuggenheimBuy—
Sep 18, 2025LUCID CAPITAL MARKETSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By